LinkinVax, a Paris, France-based clinical-stage biotechnology company, raised $4.35M in Seed funding.
Backers included André- Jacques Auberton- Hervé (co-founder and CEO of LinKinVax), Jean-Paul Kress (CEO of Morphosys), Geoffrey Duyk (US biotechnology entrepreneur and investor), Giorgio Anania, Rémi Gaston- Dreyfus and Alain Tingaud (recognized entrepreneurs in the high-tech sector).
The company intends to use the funds to accelerate the clinical development of its protein-based vaccine platform, which can be tweaked to changes and mutations in target pathogens.
Founded in 2020 and led by André-Jacques Auberton-Hervé, Honorary Chairman and founder of SOITEC, and Prof. Yves Levy, MD, PhD, immunologist, and Director of the Vaccine Research Institute (VRI/INSERM/UPEC), LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). This protein vaccine platform can adapt to changes and mutations in the target pathogens.
Bpifrance already grated LinKinVax €31m under a Covid-related PIA PSCP program and Government ”Plan Relance” , in May 2021.
FinSMEs
11/02/2022